D.E. Shaw & Co’s Pernix Therapeutics Holdings, Inc. PTX Stock Holding History

D.E. Shaw & Co’s Portfolio PTX Stock Details PTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-12,609	Closed	-$51K	–	3765
2017 Q2	$51K	Buy	+12,609	New	+$54.9K	﹤0.01%	3307
2017 Q1	–	Sell	-18,914	Closed	-$37K	–	3808
2016 Q4	$37K	Buy	+18,914	New	+$68.4K	﹤0.01%	3395
2016 Q3	–	Sell	-3,400	Closed	-$15K	–	3694
2016 Q2	$15K	Sell	3,400 -13,911	-80%	-$90.8K	﹤0.01%	3313
2016 Q1	$182K	Sell	17,311 -7,353	-30%	-$146K	﹤0.01%	3208
2015 Q4	$728K	Buy	24,664 +21,540	+690%	+$651K	﹤0.01%	2853
2015 Q3	$99K	Buy	3,124 +2,094	+203%	+$100K	﹤0.01%	3610
2015 Q2	$61K	Buy	+1,030	New	+$72.6K	﹤0.01%	3679
2014 Q4	–	Sell	-2,897	Closed	-$222K	–	4441
2014 Q3	$222K	Buy	+2,897	New	+$228K	﹤0.01%	3847

Other funds holding PTX

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co's PTX Position: Q3 2017 in Review

D.E. Shaw & Co sold out of Pernix Therapeutics Holdings, Inc. (PTX) in Q3 2017, closing a stake of 12,609 shares — an estimated $51K sold.

D.E. Shaw & Co first reported a position in PTX in Q3 2014 and held it in 8 quarters. The position peaked at $728K in Q4 2015. 32 funds tracked by Wall St. Rank hold PTX as of Q3 2017.

D.E. Shaw & Co reported no remaining Pernix Therapeutics Holdings, Inc. position as of Q3 2017 after selling out during the quarter.
D.E. Shaw & Co sold 12,609 Pernix Therapeutics Holdings, Inc. shares in Q3 2017, an estimated $51K.
D.E. Shaw & Co first reported a position in Pernix Therapeutics Holdings, Inc. in Q3 2014 and held it in 8 quarters.
D.E. Shaw & Co's Pernix Therapeutics Holdings, Inc. position peaked at $728K in Q4 2015.
32 funds tracked by Wall St. Rank held Pernix Therapeutics Holdings, Inc. as of Q3 2017.

Based on D.E. Shaw & Co's 13F filing for Q3 2017, filed 14 Nov 2017.